Syngenta Participations AG v. Controller of Patents and Designs

Relevant Acts and provisions

Patents Act, 1970

Section 117ASection 2(1)(ja)Section 3(d)

Provisions considered: Sections 2(1)(ja), 3(d) and 117A of the Patents Act, 1970, on inventive step and enhanced efficacy.

Brief facts

Syngenta appealed under Section 117A against the Controller's order refusing a patent application for a monohydrate crystalline polymorph of a fungicide compound. The Controller held that the polymorph lacked inventive step under Section 2(1)(ja), reasoning that thermal stability is an inherent, unpredictable property of polymorphs and that no unexpected effect over four cited prior-art documents was shown, and separately refused the claims as a mere new form of a known substance lacking enhanced efficacy under Section 3(d).

Issues before the Court

1. Was the Controller justified in holding that thermal stability is an inherent property of polymorphs, without citing any source, so as to deny inventive step?
2. Is efficacy under Section 3(d) confined to therapeutic efficacy, or does it extend to functional efficacy in agrochemical inventions?

Court's findings

The Court held that the Controller's finding that thermal stability is an inherent property of polymorphs was unsupported by any cited source of common general knowledge, contrary to the requirement that reliance on common general knowledge be substantiated. Relying on scientific literature on polymorphism, it observed that polymorphic behaviour is inherently unpredictable, so the appellant's data on thermal stability and reduced crystal growth in formulations could not be dismissed as obvious.

On Section 3(d), the Court observed that efficacy is a context-dependent concept and is not confined to therapeutic efficacy as understood in Novartis v. Union of India, which concerned a pharmaceutical substance. For an agrochemical invention, enhanced thermodynamic stability enabling effective application of the product amounts to an enhancement of known efficacy.

The Court recorded a finding that the invention satisfied Section 3(d), while remanding the inventive-step objection for fresh consideration applying a structured obviousness inquiry.

Decision

Appeal allowed in part; the refusal was set aside and remanded for fresh consideration of inventive step, with the Section 3(d) objection held not sustainable.

Cases cited

• Novartis AG v. Union of India & Ors., (2013) 6 SCC 1

Authorities referred to in the decision. Please verify each citation in the judgment itself.

Keywords

Efficacy Inventive Step Patent Prosecution Prior Art Section 3(d)